MediWound Ltd./$MDWD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
Ticker
$MDWD
Sector
Primary listing
Employees
121
Headquarters
Yavne, Israel
Website
MediWound Ltd. Metrics
BasicAdvanced
$179m
-
-$2.19
0.22
-
Price and volume
Market cap
$179m
Beta
0.22
52-week high
$21.26
52-week low
$13.54
Average daily volume
100k
Financial strength
Current ratio
2.41
Quick ratio
2.19
Long term debt to equity
19.617
Total debt to equity
19.617
Interest coverage (TTM)
-44.83%
Profitability
EBITDA (TTM)
-27.015
Gross margin (TTM)
19.61%
Net profit margin (TTM)
-180.30%
Operating margin (TTM)
-193.53%
Effective tax rate (TTM)
-0.57%
Revenue per employee (TTM)
$120,000
Management effectiveness
Return on assets (TTM)
-23.51%
Return on equity (TTM)
-71.82%
Valuation
Price to revenue (TTM)
11.461
Price to book
4.34
Price to tangible book (TTM)
4.34
Price to free cash flow (TTM)
-6.603
Free cash flow yield (TTM)
-15.14%
Free cash flow per share (TTM)
-2.113
Growth
Revenue change (TTM)
-24.64%
Earnings per share change (TTM)
7.04%
3-year revenue growth (CAGR)
-17.61%
10-year revenue growth (CAGR)
33.79%
3-year earnings per share growth (CAGR)
-12.29%
10-year earnings per share growth (CAGR)
-9.96%
MediWound Ltd. News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs